Rare - RARE

Ultragenyx Pharmaceutical Bolsa (NASDAQ: RARE)

Últimas noticias sobre Ultragenyx Pharmaceutical (NASDAQ:RARE) Bolsa

Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

Ultragenyx Pharmaceutical Inc. - Common Stock

Ultragenyx Pharmaceutical Inc

WISDOMTREE ENLSANDERTH UCITS USD ETF

SuperRare - United States Dollar

CANADA RARE EARTH CP ORD by Canada Rare Earth Corp.

Canada Rare Earth Corp

Cantor Fitzgerald analyst Kristen Kluska reiterates Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) with a Overweight and maintains $116 price target.

News

Price Target

Reiteration

Analyst Ratings

RARE

Cantor Fitzgerald Reiterates Overweight on Ultragenyx Pharmaceutical, Maintains $116 Price Target

In the preceding three months, 10 analysts have released ratings for Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>), presenting a wide array of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $89.2, a high estimate of $116.00, and a low estimate of $46.00. Witnessing a positive shift, the current average has risen by 3.0% from the previous average price target of $86.60.
<img src="https://www.benzinga.com/files/images/story/2024/1729540850_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The analysis of recent analyst actions sheds light on the perception of Ultragenyx Pharmaceutical by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yaron Werber</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$73.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$116.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$77.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$116.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$116.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$81.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Tiago Fauth</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$75.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$76.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$116.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Neutral</td>
<td>$46.00</td>
<td>$43.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Ultragenyx Pharmaceutical. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Ultragenyx Pharmaceutical compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Ultragenyx Pharmaceutical's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/RARE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Ultragenyx Pharmaceutical analyst ratings.</a>
<h2>Discovering Ultragenyx Pharmaceutical: A Closer Look</h2>
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
<h3>Unraveling the Financial Story of Ultragenyx Pharmaceutical</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Positive Revenue Trend: Examining Ultragenyx Pharmaceutical's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 35.75% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Ultragenyx Pharmaceutical's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -89.51% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Ultragenyx Pharmaceutical's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -45.96%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -9.0%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.09.
<h2>The Basics of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Decoding 10 Analyst Evaluations For Ultragenyx Pharmaceutical

TD Cowen analyst Yaron Werber maintains Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) with a Buy and raises the price target from $61 to $73.

TD Cowen Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $73

Biotech

General

Ultragenyx Receives FDA Breakthrough Therapy Designation For Setrusumab (UX143) To Reduce Fracture Risk In Osteogenesis Imperfecta Types I, III, And IV For Patients Aged 2 And Older

Ultragenyx Provides Update on Stage 1 Cohorts In Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy For Treatment Of Wilson Disease

RBC Capital analyst Luca Issi reiterates Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) with a Outperform and maintains $77 price target.

RBC Capital Reiterates Outperform on Ultragenyx Pharmaceutical, Maintains $77 Price Target

In the latest quarter, 10 analysts provided ratings for Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>), showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Ultragenyx Pharmaceutical, revealing an average target of $89.7, a high estimate of $116.00, and a low estimate of $45.00. Marking an increase of 1.59%, the current average surpasses the previous average price target of $88.30. 
<img src="https://www.benzinga.com/files/images/story/2024/1726855217_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A comprehensive examination of how financial experts perceive Ultragenyx Pharmaceutical is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$116.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$116.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$81.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Tiago Fauth</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$75.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$76.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$116.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Neutral</td>
<td>$46.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$111.00</td>
<td>$111.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$115.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$45.00</td>
<td>$45.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Ultragenyx Pharmaceutical. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Ultragenyx Pharmaceutical compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Ultragenyx Pharmaceutical's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Ultragenyx Pharmaceutical's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/RARE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Ultragenyx Pharmaceutical analyst ratings.</a>
<h2>Delving into Ultragenyx Pharmaceutical's Background</h2>
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
<h3>Ultragenyx Pharmaceutical's Financial Performance</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Ultragenyx Pharmaceutical's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 35.75%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Ultragenyx Pharmaceutical's net margin is impressive, surpassing industry averages. With a net margin of -89.51%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Ultragenyx Pharmaceutical's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -45.96%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Ultragenyx Pharmaceutical's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -9.0%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.09.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Ultragenyx Pharmaceutical: 10 Analysts Share Their Views

The family of Henrietta Lacks has filed a federal lawsuit in Maryland against Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) and Viatris Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>), alleging the companies profited unlawfully from the use of her tissue cells, known as &#8220;HeLa&#8221; cells.
The Lacks estate claims these cells, which were taken without her knowledge in the 1950s, have been crucial to the companies&#8217; drug developments without any compensation or permission granted to her estate.
Ben Crump, the Lacks family attorney, emphasized the historical exploitation of Black individuals in medical research, highlighting Lacks&#8217; story as a stark example.
The lawsuit follows previous actions against Thermo Fisher Scientific Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>), which has since been settled, and ongoing litigation against Ultragenyx Pharmaceutical Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>).
Related: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/38968851/ultragenyx-faces-lawsuit-over-alleged-unjust-use-of-henrietta-lacks-cells" rel="noreferrer noopener">Ultragenyx Faces Lawsuit Over Alleged Unjust Use of Henrietta Lacks&#8217; Cells</a>.
Henrietta Lacks&#8217;s cells were taken from her cervix during cancer treatment in 1951 at a Baltimore hospital.
Reuters noted that these HeLa cells were the first to survive and reproduce indefinitely in lab conditions. Lacks passed away from cervical cancer later that year at the age of 31.
The complaint details how Novartis allegedly used HeLa cells in the development of its herpes drug Famvir, cancer treatment Kymriah, and spinal muscular atrophy therapy Zolgensma.
Viatris is accused of using these cells to test its herpes drug, Denavir, and depression treatment, Mylan-Mirtazapine.
The Lacks family seeks profits from the commercialization of HeLa cells and a court order to prevent further use without permission.
Price Action: At the last check on Tuesday, NVS stock was up 0.36% at $110.25, and VTRS stock was down 0.30% at $11.53.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/08/40168977/bristol-myers-squibb-terminates-cancer-drug-development-program-with-agenus" target="_blank" rel="noreferrer noopener">Bristol Myers Squibb Terminates Cancer Drug Development Program With Agenus</a>.</li>
</ul>
Photo via Shutterstock

Large Cap

Health Care

Legal

Media

VTRS

Novartis And Viatris Sued Over Unlawful Use Of HeLa Cells Used For Cancer Treatment Drugs

Barclays analyst Gena Wang maintains Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) with a Overweight and lowers the price target from $83 to $81.

Barclays Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $81

Goldman Sachs analyst Salveen Richter maintains Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) with a Buy and raises the price target from $67 to $76.

Goldman Sachs Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $76

WIIM

Ultragenyx Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY24 revenue guidance above estimates. Also, Cantor Fitzgerald and Wedbush raised their respective price targets on the stock.

Cantor Fitzgerald analyst Kristen Kluska maintains Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) with a Overweight and raises the price target from $115 to $116.

Cantor Fitzgerald Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $116

Wedbush analyst Laura Chico maintains Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) with a Neutral and raises the price target from $43 to $46.

Wedbush Maintains Neutral on Ultragenyx Pharmaceutical, Raises Price Target to $46

Ultragenyx Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY24 revenue guidance above estimates.

2024 Full Year Financial Guidance
<ul>
<li>Total revenue guidance increased to be in the range of $530 million to $550 million (previously $500 million to $530 million)</li>
<li>Crysvita revenue expected to be towards the upper end of the range of $375 million to $400 million. This includes all regions where Ultragenyx will recognize revenue: product sales in Latin America and Turkey, royalties in Europe, which have been ongoing, and royalties in North America, which began in April 2023.</li>
<li>Dojolvi revenue in the range of $75 million to $80 million</li>
<li>Net Cash Used in Operations less than $400 million</li>
</ul>

Guidance

Ultragenyx Pharmaceutical Raises FY24 Revenue Guidance From $500M-$530M To $530M-$550M Vs $513.16M Est.

Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) reported quarterly losses of $(1.52) per share which beat the analyst consensus estimate of $(1.72) by 11.63 percent. This is a 32.44 percent increase over losses of $(2.25) per share from the same period last year. The company reported quarterly sales of $147.03 million which beat the analyst consensus estimate of $123.18 million by 19.36 percent. This is a 35.75 percent increase over sales of $108.31 million the same period last year.

Earnings

Earnings Beats

Ultragenyx Pharmaceutical Q2 EPS $(1.52) Beats $(1.72) Estimate, Sales $147.03M Beat $123.18M Estimate

Ultragenyx Pharmaceutical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) today announced that the company will share the latest clinical data, regulatory progress and program next steps for GTX-102, its investigational antisense oligonucleotide for Angelman syndrome, on Wednesday, July 24, at the 2024 Angelman Syndrome Foundation (ASF) Family Conference and Research Symposium in Sandusky, Ohio.

Ultragenyx To Present GTX-102 Angelman Syndrome Program Update At The ASF Family Conference And Research Symposium On Wednesday, July 24, 2024

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on DocGo (DCGO – Research Report), Avidity Biosciences ...

Analysts' Top Healthcare Picks: DocGo (DCGO), Avidity Biosciences (RNA)

In a report released today, Maury Raycroft from Jefferies maintained a Buy rating on Ultragenyx Pharmaceutical (RARE – Research Report), with a pri...

Jefferies Keeps Their Buy Rating on Ultragenyx Pharmaceutical (RARE)

Ultragenyx gains Breakthrough Therapy status for setrusumab for genetic disorder

In a report released today, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Ultragenyx Pharmaceutical (RARE – Research Repo...

Ultragenyx Pharmaceutical: A Strong Buy on Rare Disease Program Progress and Strategic Management

ClearBridge Mid Cap Strategy Q3 2024 Commentary

In a report released on October 11, Anupam Rama from J.P. Morgan maintained a Buy rating on Ultragenyx Pharmaceutical (RARE – Research Report), wit...

J.P. Morgan Reaffirms Their Buy Rating on Ultragenyx Pharmaceutical (RARE)

Baron Health Care Fund Q3 2024 Shareholder Letter

Analyst Yaron Werber of TD Cowen maintained a Buy rating on Ultragenyx Pharmaceutical (RARE – Research Report), boosting the price target to $73.00...

Ultragenyx Pharmaceutical: Buy Rating Affirmed with Increased Price Target and Positive EPS Outlook

TD Cowen raised the firm's price target on Ultragenyx (RARE) to $73 from $61 and keeps a Buy rating on the shares. The firm updated its model and c...

Ultragenyx price target raised to $73 from $61 at TD Cowen

Meeting to be held in San Francisco on October 21 hosted by Cantor Fitzgerald. Published first on TheFly – the ultimate source for real-time, marke...

Comments

Ultragenyx Pharmaceutical

Noticias

Últimas noticias sobre Ultragenyx Pharmaceutical (NASDAQ:RARE) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL